Novel small molecule RNA destabilizers employ a unique mechanism to specifically destabilize HBV RNA transcripts leading to reductions in HBV proteins, including HBsAg, in preclinical models.

Arbutus has identified several small molecule HBV RNA destabilizers. These therapeutics are expected to be orally available with the potential to be used in combination regimens to deliver a cure for chronic HBV. These molecules have shown complementary effects when combined with Arbutus’ HBV RNAi agents in vitro. Arbutus is focused on advancing next generation oral HBV-specific RNA destabilizers with distinct chemical scaffolds through lead optimization.